Previous 10 | Next 10 |
2023-03-10 11:19:47 ET Olema Oncology ( NASDAQ: OLMA ) will let go of ~25% of its employees across research, early development, and general and administrative functions as part of a restructuring. The move is being done so the company can focus on late-stage development of...
2023-03-10 08:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-03-10 04:58:14 ET Novartis ( NYSE: NVS ) said Sandoz will invest at least $400M to build a new biologics production plant in Lendava, Slovenia to support global demand for biosimilar therapies. The Swiss pharma giant's' generic and biosimilar unit Sandoz ...
2023-03-09 15:42:20 ET TG Therapeutics ( NASDAQ: TGTX ) launched its newly approved multiple sclerosis therapy Briumvi at $59K per year, but an influential U.S. drug pricing watchdog, says that the company should price it between $16.5K – $34.9K to meet cost-effectiveness...
2023-03-07 15:26:11 ET RothMKM has initiated Tenax Therapeutics ( NASDAQ: TENX ) with a buy saying that the company's two phase 3-ready assets for pulmonary hypertension conditions could drive growth for the company. The firm has a $6 price target (823% upside based on Mon...
2023-03-07 07:33:25 ET Tax hikes and pricing negotiations will be among the measures President Joe Biden will propose to ensure Medicare is funded for the next two decades. The plan will be part of the White House’s 2024 budget proposal, which is set for release on Thursday in Ph...
2023-03-06 19:31:03 ET Summary Several of Novartis' blockbuster drugs are nearing patent expiry, but the company's late-stage pipeline and new drug launches could offset any revenue losses. Organizational restructuring and focus on China and the U.S. could yield results. Legis...
2023-03-06 13:45:59 ET Phase 2b data for Merck's ( NYSE: MRK ) oral PCSK9 inhibitor MK-0616 has prompted the drugmaker to begin a phase 3 program in the second half of the year. Results from the mid-stage trial found that at week 8 for all four dose levels, LDL-C was ...
2023-03-06 08:13:03 ET Voyager Therapeutics ( NASDAQ: VYGR ) said that Novartis ( NYSE: NVS ) has exercised an options to license novel capsids for use in gene therapy programs against two undisclosed neurologic disorder targets. The capsids were generated fro...
Options exercised on two targets; Voyager eligible to receive associated development, regulatory, and commercial milestones, plus tiered royalties With option exercise, potential to expand agreement to include capsids for up to two additional targets extends for next 18 months CAM...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...